

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – July 11, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. May 9, 2012 DUR Minutes – Vote
 - B. May 10, 2012 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for February 2012, March 2012
 - B. Retrospective Drug Utilization Review Response for December 2011, January 2012
 - C. Medication Coverage Activity for May 2012, June 2012
 - D. Pharmacy Help Desk Activity for May 2012, June 2012

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Zioptan[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Keflex[®] 750mg – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Duexis[®] – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Botulinum Toxin Products – See Appendix F.**
 - A. Product Summary
 - B. Utilization Data
 - C. COP Recommendations
 - D. Product Details

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

9. **60 Day Notice to Prior Authorize Select Gonadotropin-Releasing Hormone Analogs for Central Precocious Puberty – See Appendix G.**
 - A. Overview
 - B. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

10. **Questions Regarding 30 Day notice to Prior Authorize Qnasl™ – See Appendix H.**
 - A. Overview
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

11. **Questions Regarding 30 Day notice to Prior Authorize Suybsys™ – See Appendix I.**
 - A. Overview
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

12. **Questions Regarding 30 Day notice to Prior Authorize Dymista™ – See Appendix J.**
 - A. Overview
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix K.**
14. **Future Business**
 - A. Annual Review of Synagis®
 - B. New Fiscal Year Annual Reviews
 - C. New Product Reviews
 - D. Medical Product Reviews

15. **Adjournment**